Every weekday morning
Lilac Early Reading Timely Update
Track medical hotspots for the first time
Ningxia confirmed a case of plague and has initiated a level 4 response
On July 19, according to the Ningxia Hui Autonomous Region Health Commission, on the 19th, a case of plague (bubonic plague) was confirmed in the General Hospital of Ningxia Medical University.
Photo source: Ningxia Hui Autonomous Region Health Commission
At present, in accordance with the requirements of the emergency plan for plague control in the autonomous region, the people’s government of the autonomous region has initiated a four-level emergency response. (Source: Ningxia Hui Autonomous Region Health Commission)
Practice credit grading evaluation for medical staff: a document issued by the health and health commission of one place
On July 15, the Chongqing Municipal Health and Health Commission issued the “Chongqing Municipal Health and Health Commission’s Notice on Printing and Distributing the Practice Credit Management Measures for Medical Practitioners in Chongqing (Trial)”, which clearly required:
p>
Photo source: Chongqing Municipal Health Commission
Chongqing will implement a graded evaluation of the practice credit of medical staff. The evaluation results are divided into grades A (excellent credit), grade B (good credit), grade C (average credit), and grades from high to low. Grade D (poor credit) and Grade E (serious dishonesty).
The impact rating dimensions include: commendation issued by the health department, experience in supporting tasks, emergency tasks such as handling public health emergencies, and penalties for violations.
Photo source: Chongqing Municipal Health Commission
Within the scope of legal authority, medical institutions may, according to the results of the credit evaluation of medical staff, perform daily supervision work such as talent project evaluation, job title declaration and appointment, and evaluation of merit and excellence, in accordance with relevant laws and regulations. , and take appropriate reward and punishment measures.
Through the health credit information system, dynamically evaluate the medical staff’s practice credit status, and the evaluation period is one year. (Source: Chongqing Municipal Health Commission)
Beijing Medical Insurance Bureau: 141 drugs will be transferred out of Beijing Medical Insurance by the end of the year
On July 12, the Beijing Municipal Medical Insurance Bureau issued the “Beijing Medical Insurance Bureau, Beijing Human Resources and Social Security Bureau on the announcement of the city’s third batch of non-national medical insurance drug catalogues. Notice”, which clearly states:
Source: Beijing Municipal Medical Insurance Bureau
141 non-national medical insurance drug catalogues such as “Cefonisir Injection” have been deleted from the Beijing Medical Insurance Drug Catalogue and are no longer included in the scope of reimbursement. The notice will take effect from December 31 this year.
On July 20, the Beijing Municipal Medical Insurance Bureau further explained the notice, saying that the amlodipine, clarithromycin, ibuprofen and other drugs that were not listed in the national medical insurance drug list were called out. Only a certain dosage form of the related drug was deleted, and similar drugs are still in the medical insurance catalog. (Source: Beijing Municipal Medical Insurance Bureau)
Shanghai: Free testing services at normalized nucleic acid testing sites extended to August 31
On July 20, Shanghai held a press conference on epidemic prevention and control, at which it was stated that the normalized nucleic acid testing sites in Shanghai will continue to provide free testing services until August 31. (Source: Published in Shanghai)
Image source: Published in Shanghai
Nature: The research and development direction of new crown drugs is changing, and the research and development of drugs for mild symptoms is gradually starting to pay attention.
On July 18, Nature published an article saying that the research and development direction of new crown drugs is changing. In addition to severe treatment, some researchers have begun to pay attention to the development of mild treatment drugs.
While WHO recommends more than six COVID-19 drugs for patients with severe symptoms of the new crown or at risk of hospitalization, it also warns against using these drugs as a treatment for mild symptoms— Also, the WHO does not recommend what medicines should be taken for patients with mild symptoms.
Image source: Nature
Nature thinks drugs to treat mild symptoms could mark a turning point in the pandemic. Such treatments not only allow people to get back to life faster, but also limit the spread of the disease. Fewer infections means fewer chances for the virus to mutate, so drugs to treat milder illnesses can stop new variants from emerging.
Low-income countries can also benefit. In the Democratic Republic of Congo, for example, only 3.3% of the population is vaccinated. But drugs can help make up for low vaccination rates. Also, many drugs are easier to deploy in Africa than vaccines, which often require refrigeration and must be administered by trained personnel.
Immunologist Marc Feldmann of the University of Oxford, UK, points to another benefit: Researchers don’t fully understand the risk factors for severe illness. So widespread use of treatments for mild cases could save the lives of those who didn’t know they were at high risk.
Image source: Nature
However, there are barriers to finding drugs to treat people with mild symptoms. Edward Mills, a health researcher at McMaster University in Canada, said treatment guidelines, including those issued by organizations such as the World Health Organization, focus on severe cases. Research on such drugs is unlikely to be useful if guidelines discourage doctors from prescribing them for people with mild symptoms of Covid-19. (Source: Nature)
Guangdong has more than 300 cases of infection in a month, and 15 places in the province have reported
According to statistics from the Guangdong Provincial Health and Health Commission, this round of epidemic in Guangdong started on June 18 and has lasted for a month. As of 24:00 on July 19, Guangdong Province has reported more than 300 local infections.
Photo source: Guangdong Provincial Health Commission
Since June 18, the epidemic in Guangdong Province has involved Guangzhou, Zhuhai, Shenzhen, Zhongshan, Foshan, Qingyuan, Maoming, Shaoguan, Jiangmen, Dongguan, Zhanjiang, Yangjiang, Shantou, Heyuan, Huizhou and more land. (Source: Guangdong Provincial Health Commission, People’s Daily Health Client)
108 new local confirmed cases in 31 provinces, municipalities and autonomous regions on the 19th
From 0 to 24:00 on July 19, 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps reported 150 new confirmed cases. Among them, there are 108 local cases (47 in Gansu, 21 in Guangxi, 20 in Guangdong, 7 in Sichuan, 5 in Shanghai, 4 in Anhui, 3 in Jiangxi, and 1 in Beijing), including 29 who were converted from asymptomatic infections to confirmed cases cases (22 in Gansu, 5 in Sichuan, 1 in Beijing, and 1 in Guangdong). No new deaths were reported. No new suspected cases were reported. (Source: National Health Commission)
Issue 870Lilac Early Reading ends here
Planning: Fruit
The source of the title map: Zhanku Hailuo